SAB Biotherapeutics, Inc.
SABSW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $10.5K in total; no superinvestor holds it.
Other share classesSABS
13F holders, Q4 2021
Institutional positions in SAB Biotherapeutics, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- +22 vs. Q3 2021
- Shares held
- 1.82M
- +1.82M vs. Q3 2021
- Total value
- $3.10M
- +$3.10M vs. Q3 2021
- New holders
- 22
- 0 more added
- Sold out
- 0
- 0 more reduced
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SABSW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 8 | $10.5K |
| Q1 2026 | 6 | $21.1K |
| Q4 2025 | 7 | $8.34K |
| Q3 2025 | 10 | $19.5K |
| Q2 2025 | 6 | $26.7K |
| Q1 2025 | 7 | $28.1K |
| Q4 2024 | 9 | $66.3K |
| Q3 2024 | 9 | $22.3K |
| Q2 2024 | 11 | $52.1K |
| Q1 2024 | 12 | $43.8K |
| Q4 2023 | 10 | $38.1K |
| Q3 2023 | 9 | $93.0K |
| Q2 2023 | 10 | $88.4K |
| Q1 2023 | 14 | $51.6K |
| Q4 2022 | 13 | $57.9K |
| Q3 2022 | 16 | $84.0K |
| Q2 2022 | 14 | $262.0K |
| Q1 2022 | 13 | $724.0K |
| Q4 2021 | 22 | $3.10M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding SAB Biotherapeutics, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Tower Research Capital LLC (TRC) | 48 | $0 | 0.00% | +48 | New |
| UBS Group AG | 2,888 | $5.00K | 0.00% | +2,888 | New |
| JPMorgan Chase & Co | – | $21.0K | 0.00% | – | New |
| Jane Street Group, LLC | 13,550 | $24.0K | 0.00% | +13,550 | New |
| Walleye Trading LLC | 15,505 | $28.0K | 0.00% | +15,505 | New |
| Bluefin Capital Management, LLC | 19,249 | $34.0K | 0.00% | +19,249 | New |
| Citadel Advisors LLC | 19,628 | $35.0K | 0.00% | +19,628 | New |
| Context Capital Management, LLC | 24,203 | $38.0K | 0.00% | +24,203 | New |
| Walleye Capital LLC | 23,258 | $42.0K | 0.00% | +23,258 | New |
| Morgan Stanley | 31,407 | $56.0K | 0.00% | +31,407 | New |
| Fort Baker Capital Management LP | 36,693 | $66.0K | 0.01% | +36,693 | New |
| HRT Financial LP | 44,982 | $80.0K | 0.00% | +44,982 | New |
| Equitec Proprietary Markets, LLC | 45,000 | $81.0K | 0.04% | +45,000 | New |
| Rivernorth Capital Management, LLC | 46,665 | $84.0K | 0.00% | +46,665 | New |
| Maven Securities LTD | 50,000 | $90.0K | 0.01% | +50,000 | New |
| Integrity Capital Management (HK) Ltd | 54,433 | $97.0K | 0.31% | +54,433 | New |
| CVI Holdings, LLC | 58,320 | $104.0K | 0.01% | +58,320 | New |
| Yakira Capital Management, Inc. | 115,785 | $207.0K | 0.03% | +115,785 | New |
| Balyasny Asset Management LLC | 281,107 | $503.0K | 0.00% | +281,107 | New |
| Shaolin Capital Management LLC | 841,795 | $1.51M | 0.04% | +841,795 | New |
| Radcliffe Capital Management, L.P. | 80,897 | – | – | +80,897 | New |
| LMR Partners LLP | 16,300 | – | – | +16,300 | New |